Get the Stockscreener App
1.34
7.59%
-0.11
After Hours:
1.36
0.02
+1.49%
Biovie Inc stock is traded at $1.34, with a volume of 82,700.
It is down -7.59% in the last 24 hours and up +26.42% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.45
Open:
$1.45
24h Volume:
82,700
Relative Volume:
0.81
Market Cap:
$10.10M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.2577
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
+5.51%
1M Performance:
+26.42%
6M Performance:
-22.99%
1Y Performance:
+9.84%
1-Day Range:
$1.29
$1.45
1-Week Range:
$1.25
$1.45
52-Week Range:
$0.62
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.34 | 10.93M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie Inc. (BIVI) Discusses Clinical Progress of - One News Page
BIVI SEC FilingsBiovie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioVie Inc. (BIVI) Competitors - Meyka
BIVI,CYRX Dividends - Finviz
BioVie (BIVIW) 10K Form and SEC Filings 2026 - MarketBeat
BioVie (BIVIW) Stock Price, News & Analysis - MarketBeat
BioVie (BIVIW) Stock Chart and Price History 2026 - MarketBeat
BioVie (BIVIW) Stock Trends and Sentiment 2026 - MarketBeat
Top BioVie (BIVIW) Competitors 2026 - MarketBeat
Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI) - The Wall Street Transcript
BIVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth - The Destin Log
New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew - Newport Daily News
60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
BIVIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioVie to host investor webinar on March 4 - Proactive financial news
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4 - Bitget
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4 - The Manila Times
Alzheimer’s and Long COVID drug update: BioVie plans March 4 webcast - Stock Titan
Aug Shorts: Will BioVie Inc stock go up in YEARMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn
BioVie stock dips on pricing $12M securities offering - MSN
BioVie Inc. (NASDAQ:BIVI) Sees Significant Increase in Short Interest - Defense World
Why BioVie Inc. stock is recommended by analystsPortfolio Gains Report & Weekly High Return Stock Opportunities - mfd.ru
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive Investors
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting - Bitget
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
BioVie highlights bezisterim research at ACP meeting - Yahoo! Finance Canada
BioVie could offer first new Parkinson’s therapy in decades - Yahoo! Finance Canada
EV Market: Is BioVie Inc a turnaround storyQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Key facts: BioVie Inc. reports $6.1M Q4 loss; faces operational issues - TradingView
BIOVIE INC. SEC 10-Q Report - TradingView
BIVI: Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist - TradingView
Aug Sentiment: Will BioVie Inc stock go up in YEARTrade Entry Report & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Setup Watch: Will BioVie Inc stock go up in YEARWeekly Trading Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Trading Recap: What are the analyst revisions for BioVie IncIs Olympic Steel Inc stock a good investment in YEARForecast Cut & Short-Term High Return Ideas - baoquankhu1.vn
Aug Mood: Is BioVie Inc. forming a bullish divergenceJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - mfd.ru
Option Therapeutics files for IPO of 2.3 million shares of common stockSEC filing - marketscreener.com
Option Therapeutics, Clinical-Stage Developer of Liver Disease Therapies, Files for NYSE American IPO - TradingView
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of BioVie Inc. (BIVI) - accessnewswire.com
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):